Aiming To Lead A Global Operation? Start In China!
Executive Summary
Moving from China president to a CEO, from regional Asia head to a global pharmaceutical president, several recent senior executive appointments have people wondering if China is increasingly becoming the new launch pad for high flyers eyeing a global pharma leadership role.
You may also be interested in...
Asia Executives To Watch: Novartis China, GSK India, Cipla
Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.
Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
What Lies Beneath China's Steep Price Cuts For New Drugs
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Need a specific report? 1000+ reports available
Buy Reports